Vaxcyte, Inc. (PCVX)
Develops vaccines to prevent bacterial infections like pneumococcal disease and strep.
$55.42-0.00%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+67.8%
The outlook
Analysts are strongly bullish on PCVX, with a consensus rating near 1.3 out of 5. The stock trades above its key moving averages and sits about three-quarters of the way up its 52-week range. The average analyst price target sits roughly 97% above the current price.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 9 analysts
Price trendAbove its 50- & 200-day averages
52-week range73% of the way from its 52-week low to high
Price targetAvg target +97% vs current price
Analyst price target
~12-month · 9 analysts$109.00average target+96.7% vs now
Now $55.42
Low $67.00High $163.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$8.00B
52-wk high
$65.00
52-wk low
$29.08
50-day avg
$52.65
200-day avg
$51.82
Trailing P/E
—